Proof of Concept to Clinical Confirmation: Evolving Clinical Trial Designs for Targeted Agents. (3rd June 2012)

• Record Type: Journal Article
• Authors: Finn, Laura; Tan, Winston
• Other Names: Amichetti M. Academic Editor.; Franken N. A. Academic Editor.; Loizidou M. Academic Editor.
• Is Part Of: ISRN oncology. Volume 2012(2012)
• Publication Date: 2012-06-03
• Subjects: Oncology -- Periodicals; Neoplasms; Oncology; Periodicals; 616.994
• DOI: 10.5402/2012/478607
• Languages: English
• ISSNs: 2090-5661

Abstract

Abstract : No single therapy benefits the majority of patients in the practice of oncology as responses differ even among patients with similar tumor types. The variety of response to therapy witnessed while treating our patients supports the concept of personalized medicine using patients' genomic and biologic information and their clinical characteristics to make informed decisions about their treatment. Personalized medicine relies on identification and confirmation of biologic targets and development of agents to target them. These targeted agents tend to focus on subsets of patients and provide improved clinical outcomes. The continued success of personalized medicine will depend on the expedited development of new agents from proof of concept to confirmation of clinical efficacy.